These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
362 related items for PubMed ID: 15645737
1. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients]. Ogi M, Horiuchi T, Abe R, Wakabayashi M, Wakabayashi T. Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737 [Abstract] [Full Text] [Related]
3. [Iron replacement in hemodialysis patients with a normal serum ferritin level]. Riedel MK, Morgenstern T. Dtsch Med Wochenschr; 2004 Sep 03; 129(36):1849-53. PubMed ID: 15368155 [Abstract] [Full Text] [Related]
4. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders. Takasawa K, Takaeda C, Wada T, Ueda N. Nutrients; 2018 Mar 29; 10(4):. PubMed ID: 29596361 [Abstract] [Full Text] [Related]
5. Iron supplementation in haemodialysis--practical clinical guidelines. Silva J, Andrade S, Ventura H, Santos JP, Colaço S, Oliveira C, Ponce P. Nephrol Dial Transplant; 1998 Oct 29; 13(10):2572-7. PubMed ID: 9794562 [Abstract] [Full Text] [Related]
6. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients. Dittrich E, Schillinger M, Sunder-Plassmann G, Hörl WH, Vychytil A. Perit Dial Int; 2002 Oct 29; 22(1):60-6. PubMed ID: 11929146 [Abstract] [Full Text] [Related]
7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Am J Kidney Dis; 2006 Apr 29; 47(4):644-54. PubMed ID: 16564942 [Abstract] [Full Text] [Related]
8. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Kidney Int; 1999 Jun 29; 55(6):2477-86. PubMed ID: 10354297 [Abstract] [Full Text] [Related]
9. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Taylor JE, Peat N, Porter C, Morgan AG. Nephrol Dial Transplant; 1996 Jun 29; 11(6):1079-83. PubMed ID: 8671972 [Abstract] [Full Text] [Related]
10. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, DRIVE Study Group. J Am Soc Nephrol; 2007 Mar 29; 18(3):975-84. PubMed ID: 17267740 [Abstract] [Full Text] [Related]
11. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Lin CL, Hsu PY, Yang HY, Huang CC. Ren Fail; 2003 May 29; 25(3):445-53. PubMed ID: 12803508 [Abstract] [Full Text] [Related]
12. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. Macdougall IC, Dahl NV, Bernard K, Li Z, Batycky A, Strauss WE. BMC Nephrol; 2017 Apr 03; 18(1):117. PubMed ID: 28372549 [Abstract] [Full Text] [Related]
13. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Am J Kidney Dis; 1996 Feb 03; 27(2):234-8. PubMed ID: 8659499 [Abstract] [Full Text] [Related]
14. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. Pollak VE, Lorch JA, Shukla R, Satwah S. BMC Nephrol; 2009 Feb 26; 10():6. PubMed ID: 19245700 [Abstract] [Full Text] [Related]
15. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients. Deira J, González-Sanchidrián S, Polanco S, Cebrián C, Jiménez M, Marín J, Gómez-Martino JR, Fernández-Pereira L, Tabernero J. Ren Fail; 2016 Aug 26; 38(7):1076-81. PubMed ID: 27197731 [Abstract] [Full Text] [Related]
16. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels. Chen WT, Lin YF, Yu FC, Kao WY, Huang WH, Yan HC. Am J Kidney Dis; 2003 Jul 26; 42(1):158-66. PubMed ID: 12830468 [Abstract] [Full Text] [Related]
17. Influence of intravenous iron therapy on novel markers of iron deficiency. Chinnappa S, Bhandari S. Int J Artif Organs; 2010 May 26; 33(5):297-301. PubMed ID: 20593351 [Abstract] [Full Text] [Related]
18. [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia]. Cançado RD, Brasil SA, Noronha TG, Chiattone CS. Rev Assoc Med Bras (1992); 2005 May 26; 51(6):323-8. PubMed ID: 16444338 [Abstract] [Full Text] [Related]
19. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. Deira J, Diego J, Martínez R, Oyarbide A, González A, Díaz H, Grande J. J Nephrol; 2003 May 26; 16(5):703-9. PubMed ID: 14733417 [Abstract] [Full Text] [Related]
20. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Am J Kidney Dis; 1999 Mar 26; 33(3):471-82. PubMed ID: 10070911 [Abstract] [Full Text] [Related] Page: [Next] [New Search]